Objective: The World Health Organization recommends tranexamic acid (TXA) in the management of postpartum hemorrhage (PPH). However, the role of TXA in PPH prevention and the optimal timing of TXA administration remain unknown. Our objective was to describe the timing of TXA administration, differences in timing of TXA administration by mode of delivery, and current trends in TXA administration in the United States.
Study Design: We conducted a descriptive study of trends in TXA administration using the Cerner Real-World Database. We identified 1,544,712 deliveries occurring at greater than 24 weeks' gestation from January 1, 2016, to February 21, 2023. Demographic data were collected including gestational age, mode of delivery, and comorbidities. The timing of TXA administration and differences in TXA timing by mode of delivery were also collected.
Results: In our cohort, 21,433 patients (1.39%) received TXA. The majority of patients who received TXA were between ages 25 and 34 years old (55.3%), White (60.7%), and delivered between 37 and 41 weeks (81.4%). The TXA group had a higher prevalence of medical comorbidities including obesity (32.9 vs. 19.0%, < 0.00001), preeclampsia (19.6 vs. 6.81%, < 0.00001), and pregestational diabetes (3.27 vs. 1.36%, < 0.00001). Among women who received TXA, 15.4% received it within 3 hours before delivery. Among patients who received TXA after delivery, 23.6% received TXA within 3 hours after delivery, whereas 35.7% received TXA between 10 and 24 hours after delivery. A total of 80.4% of patients who received TXA before delivery had a cesarean delivery.
Conclusion: While TXA is most commonly administered after delivery, many patients are receiving TXA prior to delivery in the United States without clear evidence to guide the timing of administration. A randomized trial is urgently needed to determine the safety and efficacy of TXA when administered prior to delivery.
Key Points: · TXA is used in the treatment of PPH.. · The role of TXA in prevention of PPH is unclear.. · Fewer than 2% of patients in the United States receive TXA at delivery.. · TXA administration before delivery in the United States is rising..
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-2353-0832 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy, safety and dose patterns of tranexamic acid in meningioma surgery: a systematic review and updated meta-analysis of randomized controlled trials.
Neurosurg Rev
January 2025
Department of Medicine, Federal University of Sergipe, Aracaju, Brazil.
We reviewed the efficacy and safety of intravenous administration of tranexamic acid (TXA) in randomized trials involving patients undergoing intracranial meningioma resection surgery, with special emphasis on the effects of different dosages. A comprehensive search was conducted in the following databases: Cochrane, PubMed, Embase, Scopus, Lilacs, and Web of Science. Two reviewers independently screened titles and abstracts, reviewed the full texts and collected data.
View Article and Find Full Text PDFEffectiveness of Inhalational Tranexamic Acid in Patients with Nonmassive Hemoptysis-A Systematic Review and Meta-Analysis.
Lung
January 2025
Department of Emergency Medicine, Aarupadai Veedu Medical College and Hospital, Vinayaka Missions Research Foundation, Puducherry, India.
Background: Hemoptysis, the expectoration of blood from the lower respiratory tract, varies in severity and necessitates effective management to mitigate morbidity. Traditional treatments include bronchial artery embolization and pharmacological approaches. Tranexamic acid (TXA), an antifibrinolytic agent known for its efficacy in reducing bleeding during surgery and trauma, is being explored for its efficacy in treating Hemoptysis via both intravenous and inhalational routes.
View Article and Find Full Text PDFThe optimal dose of intravenous tranexamic acid for reducing blood loss in spinal surgery: a network meta-analysis.
BMC Musculoskelet Disord
December 2024
Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Background: This study aims to evaluate the optimal dose of intravenous tranexamic acid (TXA) for reducing blood loss in spinal surgery.
Methods: A systematic search was conducted in the PubMed, Embase, Cochrane Library database from inception until November 2023. Randomized controlled trials (RCTs) incorporating diverse TXA dosing regimens for spinal surgery were included.
Tranexamic acid in hip and spine surgery for children with cerebral palsy - a PRISMA-compliant scoping review.
Syst Rev
December 2024
Department of Paediatrics, The Royal Children's Hospital, University of Melbourne, 50 Flemington Road, Parkville, VIC, 3052, Australia.
Many children with cerebral palsy (CP) are frail and require major hip and/or spine surgeries associated with substantial blood loss. Tranexamic acid (TXA) is commonly used to reduce blood loss, but there is uncertainty around the optimal dose and timing of administration. There have been reviews in sub-populations and specific dosing regimens, but a broad overview of the available literature is lacking.
View Article and Find Full Text PDFThe efficacy and safety of topical combined with intravenous administration of tranexamic acid in spine surgery: a systematic review and meta-analysis.
BMC Musculoskelet Disord
December 2024
Department of Orthopedics, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, 317000, China.
Background: There is controversy regarding the efficacy of intravenous combined topical tranexamic acid. We conducted this study to systematically assess the effectiveness of intravenous combined topical tranexamic acid (combined TXA) in spinal surgery to guide clinical practice.
Methods: The review process was conducted according to the PRISMA guidelines.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!